This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Alphagan P

Allergan plc

Drug Names(s): Aiphagan P (Japan), brimonidine tartrate ophthalmic solution

Description: Alphagan P is a relatively selective alpha-2 adrenergic agonist for ophthalmic use, resulting in an ocular hypotensive effect. Phamacologic studies suggest brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

Deal Structure: Allergan and Kyorin
In May 2004, Allergan announced that it has entered into an exclusive licensing agreement with Kyorin in Japan to develop and market the ALPHAGAN/ ALPHAGAN P Franchise. Subsequently, Kyorin sub-licensed this right to Senju.

Under the terms of the licensing agreement, Kyorin will be responsible for the development and commercialization of ALPHAGAN/ ALPHAGAN P in Japan and will incur associated costs. Kyorin will provide Allergan with an up-front payment, as well as development and commercialization milestone payments. In addition, Kyorin will pay Allergan a royalty based on product sales. Allergan and Kyorin will work collaboratively on overall product strategy and management.

Actavis and Allergan
In November 2014, Actavis and Allergan announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common...See full deal structure in Biomedtracker

Partners: Kyorin Pharmaceutical Co., Ltd. Senju Pharmaceutical Co., Ltd.


Alphagan P News

Pink Sheet Allergan Alphagan P


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug